AUKAT: Conditional VAE-Driven Augmentation and Neural Modeling of Enzyme Turnover Numbers

CatESO: Differentiable Enzyme Sequence Optimization Guided by Substrate-Aware kcat Prediction

An ensemble learning framework for protein stability prediction with enhanced recognition of stabilizing mutations

Three modeling frameworks are developed, including models based on handcrafted features, models using embedding representations extracted from ProteinMPNN, and ensemble models integrating a diverse set of state‐of‐the‐art predictors integrating a diverse set of state‐of‐the‐art predictors.

Rethinking Benchmarks and Models for Enzyme Specificity Prediction

Four recently released ES and ER prediction models are benchmarked and it is suggested that interaction-aware representations from full biomolecular complexes may provide a promising basis for enzyme prioritization.

Sequence-centric deep learning druggability prediction using protein language models with multi-scale attention and feature fusion

Sequence-based protein druggability classification can support early target triage when structural information is unavailable, uncertain, or inconsistently linked to druggability labels. We present DrugPLMFormer, a sequence-first retrospective screening framework that combines frozen protein language model embeddings with self-attentive BiLSTM encoding, Transformer-based long-range modeling, optional physicochemical feature fusion, and compute-budgeted BO–CTCM model selection. Hyperparameters were selected through multi-fidelity screening within an approximately 200-evaluation budget, using a validation objective that combined AUPRC and MCC to balance threshold-free discrimination with operating-point stability, rather than to imply unrestricted generalization. On ProTar-II, using a 50% sequence-identity homology-aware split, DrugPLMFormer achieved 95.98% accuracy, 96.01% F1-score, 96.42% sensitivity, 95.61% specificity, and 0.981 ROC-AUC. Without using external data for training, tuning, threshold selection, or early stopping, the selected model showed favorable held-out mean performance on ProTar-II-Ind (96.62% accuracy, 0.9688 ROC-AUC) and DPI_CDF (96.20% accuracy, 0.9696 ROC-AUC). Paired external analyses indicated that accuracy and F1-score differences were numerically favorable but not statistically significant, whereas the ROC-AUC improvement on DPI_CDF was statistically supported. Train-to-external homology analysis showed that most external proteins had less than 50% sequence identity to the training set, although residual dataset shift and label heterogeneity may still affect generalization. With cached PLM embeddings, downstream CPU inference required approximately 1.0–1.2 ms per sequence, excluding tokenization and ESM-2 embedding generation. Overall, DrugPLMFormer provides a reproducible, leakage-aware framework for retrospective sequence-based druggability screening and target prioritization, while prospective validation and experimental confirmation remain necessary before operational deployment.

Smiles-based bioactivity prediction through molecular encoder selection and data augmentation.

Quantitative prediction of inhibitor potency can accelerate early-stage drug discovery. Recently, data-driven approaches have gained widespread interest in drug discovery, as evidenced by a growing number of benchmarking challenges and open competitions. In this context, we developed a machine learning-based methodology that can find the most effective way of predicting IC50 values against ASK1 from SMILES, for "Jump AI(.py) 2025: 3rd AI Drug Discovery Competition", hosted by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) on the Dacon platform. Applying our methodology achieved the highest overall predictive performance among all participating teams. Beyond this competition setting, we present a compact SMILES-based modeling workflow comprising (i) a pre-trained encoder, (ii) regression models, (iii) data augmentation, and (iv) hyperparameter tuning. We systematically compared molecular representations from sequence- and graph-based models, including ChemBERTa-2 and MolCLR. Across encoder-regressor combinations, ChemBERTa-77 M-MLM embeddings paired with support vector regression (SVR) yielded the strongest predictive performance. Embedding-level mix-up augmentation and SVR hyperparameter tuning further improved predictive performance. Our findings highlight that careful SMILES preprocessing and encoder selection have a critical influence on IC50 values and provide a reproducible benchmark for single-target bioactivity prediction, thus contributing to a more efficient drug discovery process. Scientific Contribution In this study, we propose a machine learning methodology for predicting the IC50 values of ASK1 inhibitors from SMILES representations, with a systematic comparison of molecular encoders and regression models. Our results show that the use of suitable encoder-regressor pairs together with embedding-level mix-up augmentation improves model generalizability without requiring SMILES-level augmentation. This strategy would be particularly useful for settings with imbalanced labels or limited data, and could be applied more broadly to IC50 prediction for other kinase inhibitors.

ThermoFusion: A Multimodal Deep Learning Framework for Generalizable Prediction of Enzyme Thermostability

ThermoFusion, a hybrid deep learning framework that integrates 3D protein structure embeddings from ThermoMPNN with sequence-based embeddings from the pretrained protein language model ESM2 to predict the effects of single-point mutations on protein stability is presented.